title: [Dilated cardiomyopathy: recent advances and current treatment].
abstract: The combination of dilatation and systolic dysfunction of the left or both ventricles from idiopathic or specific origin define dilated cardiomyopathy (DC). It is an important cause of cardiac morbidity through congestive heart failure (CHF) or arrhythmias. Prevalence studies estimate a rate of left ventricular systolic dysfunction of 2% to 3% or more, and of 1.5% of CHF among the general population. Genetic studies on familial DC have identified at least 5 genetic locus. In addition, the role of virus, genetic abnormalities, immunologic responses and increased myocardial apoptosis are factors recognized factors that play a significant role in the pathogenesis of idiopathic DC. Mortality in severe CHF may reach 50% at 2 years after diagnosis. The introduction of "triple" therapy combining diuretics, digoxin and angiotensin converting enzyme inhibitors (ACEI) has significantly decreased this high mortality. Recent large, multicentric clinical trials on drugs aimed to diminish the neuroendocrine hyperactivity of patients in stable chronic CHF (betablockers and spirolactone) have resulted in an additional reduction in total mortality of about 35% in relation with control groups. Betablockers, compared to ACEI, also diminish the rate of sudden death prompting their almost mandatory indication in the absence of contraindications. Cardiac transplantation presently offers a survival rate of 66% at 5 years but donor scarcity has stabilized the number of procedures. In patients resuscitated from malignant arrhytmias the implantation of defibrillators offers a better survival than drugs. Future advances in the knowledge of the pathogenesis and especially of genetic mechanisms, may substantially change the understanding and treatment of these disorders.
authors.affiliation: Profesor Titular de Medicina. Centro Médico. Caracas. Venezuela. hacquetalla@true.net
authors.forename: H
authors.initials: H
authors.lastname: Acquatella
mesh_terms: D002311:Cardiomyopathy, Dilated / Q000473:pathology / Q000628:therapy*; D006801:Humans